Related Experiment Video
Updated: May 7, 2026

Vessel-sparing Excision and Primary Anastomosis
Published on: January 7, 2019
[ASA and clopidogrel for urological operations. Perioperative management]
Insights
Discontinuing aspirin (acetylsalicylic acid, ASA) therapy significantly increases cardiovascular risks, including heart attack and death. This risk is elevated threefold, even after long-term use, emphasizing the need for continuous aspirin therapy.
Area of Science:
- Cardiology
- Pharmacology
- Urology
Background:
- Aspirin (acetylsalicylic acid, ASA) is widely used for secondary cardiovascular disease prevention.
- Discontinuation of ASA therapy may impact patient outcomes.
- The perioperative management of patients on antiplatelet therapy, especially in urological surgery, requires careful consideration.
Purpose of the Study:
- To evaluate the association between aspirin adherence and cardiovascular events.
- To assess the impact of aspirin withdrawal on adverse cardiovascular outcomes.
- To review bleeding risks associated with aspirin and clopidogrel in urological surgery.
Main Methods:
- Systematic overview and meta-analysis.
- Inclusion of over 50,000 patients at risk for coronary artery disease.
- Analysis of studies on aspirin and clopidogrel use in urological surgery.
Main Results:
- Non-adherence or discontinuation of aspirin significantly increased the risk of non-fatal myocardial infarction or death.
- Withdrawal of low-dose aspirin was linked to a threefold increase in adverse cardiovascular events.
- Increased bleeding in urological surgery with aspirin/clopidogrel did not translate to significant morbidity.
Conclusions:
- Chronic low-dose aspirin should not be discontinued for secondary cardiovascular prevention.
- The cardiovascular benefits of continuous aspirin therapy outweigh potential bleeding risks in most surgical contexts.
- Multidisciplinary perioperative management is crucial for patients with drug-eluting stents on dual antiplatelet therapy.
Abstract:
In a systematic overview and meta-analysis among more than 50,000 patients at risk for coronary artery disease, not adhering to or discontinuing aspirin (acetylsalicylic acid, ASA) was associated with a significantly increased risk of non-fatal myocardial infarction or death. Withdrawal of low dose aspirin was correlated with a threefold increase in the risk of adverse cardiovascular events. This risk is present irrespective of the length of time patients had been taking low dose aspirin. Therefore, in patients on chronic low dose aspirin for secondary prevention of cardiovascular disease, aspirin should never be discontinued. In the few available studies in urological surgery the increase in bleeding does not translate into a significant increase in specific morbidity. This seems to be also true for the additional administration of clopidogrel to aspirin. Nevertheless, in patients with drug-eluting stents and dual antiplatelet therapy, urologists should ensure a multidisciplinary management of the perioperative course.
Related Concept Videos
Aneurysm IV: Nursing Management
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Calculi III: Medical Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
